The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study.
Saroj Niraula
No relevant relationships to disclose
Ryan JO Dowling
No relevant relationships to disclose
Marguerite Enis
No relevant relationships to disclose
Martin Chang
No relevant relationships to disclose
Susan Done
No relevant relationships to disclose
Nicky Hood
No relevant relationships to disclose
Jaime Escallon
No relevant relationships to disclose
Wey Leong
No relevant relationships to disclose
David R. McCready
No relevant relationships to disclose
Michael Reedijk
No relevant relationships to disclose
Vuk Stambolic
No relevant relationships to disclose
Pamela Jean Goodwin
No relevant relationships to disclose